Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.
Ajai Chari, MD, Mount Sinai Hospital
Advertisement
Articles by Ajai Chari, MD, Mount Sinai Hospital
Advertisement
Latest Updated Articles
Updates in Multiple Myeloma in the Frontline SettingJanuary 29th 2021
Updates in Relapsed/Refractory MyelomaJanuary 29th 2021
Third and Subsequent Line Options for Multiple MyelomaJanuary 29th 2021
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer
5